+91-8668442535

Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Combination ACE Inhibitors), By Applications (Hypertension, Coronary Artery Diseases, Heart Failure, Myocardial Infarction, Diabetes, Chronic Kidney Disorders) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2023

This report, titled "Angiotensin-converting enzyme (ACE) Inhibitors Market Studies," studies various drug types, application types, and geographical scenarios. According to the Cleveland Clinic, an ACE inhibitor is a vasodilator that dilates the blood vessels to improve the amount of blood the heart pumps in patients suffering from high blood pressure. An ACE inhibitor also increases blood flow, which will help decrease the amount of work the heart has to do and may also decrease your blood pressure. The renin-angiotensin-aldosterone system (RAAS) plays a key physiologic role in regulating blood pressure in the human body. In RAAS, ACE plays an important role in the production of angiotensin II, facilitating the conversion of the biologically inactive angiotensin I to angiotensin II. Angiotensin II increases blood pressure by its action as a potent vasoconstrictor and stimulates the production of aldosterone, which promotes sodium and water retention in the body.

Therefore, a substance that inhibits ACE will decrease the production of angiotensin II and reduce blood pressure. According to the World Health Organization (WHO), high blood pressure is one of the most important causes of premature death worldwide, killing nearly 9.4 million people yearly, and the problem is growing. The WHO data further suggested that the prevalence of raised blood pressure was highest in the African Region (46%) and lowest in the Region of the Americas (35%). In the Southeast Asia Region, 36% of adults have hypertension. Thus, the rising prevalence of hypertension and diabetes and the high public awareness related to the early diagnosis and management of these disorders are the key factors assisting the overall ACE inhibitor market.

For this study, the global ACE inhibitors market is segmented based on drug type into benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, and combination ACE inhibitors. Market size estimates and forecasts for these segments for 2013–2023 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for 2016–2023, considering 2015 as the base year.

For this study, the global ACE inhibitors market is segmented based on application type into hypertension, coronary artery disease, heart failure, myocardial infarction, diabetes, chronic kidney disease, scleroderma, migraine, and others. Market size estimates and forecasts for these segments for 2013–2023 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for 2016–2023, considering 2015 as the base year.

The ACE inhibitors market has been geographically categorized into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Each geography market is further split to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, Brazil, and the GCC countries. The market size and forecast for these segments during 2013–2023 and their CAGRs for the period 2016–2023 are provided in this report.

The major key players profiled in the ACE inhibitors market are based on various characteristics such as business description, financial health, budget allocation, product portfolio, and news coverage. The key players profiled in this report are Abbott Laboratories, Pfizer, Inc., Novartis AG, Merck & Co., Astra Zeneca plc, Johnson & Johnson Limited, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., and others.

Based on the type of application, the global angiotensin-converting enzyme (ACE) inhibitors market is segmented as follows:

  • Hypertension
  • Coronary artery diseases
  • Heart Failure
  • Myocardial Infarction
  • Diabetes
  • Chronic Kidney Disorders
  • Others (Scleroderma, migraine, and others)

In the base year 2015, hypertension and diabetes applications collectively accounted for the largest market share and are expected to maintain their dominance throughout the forecast period of 2016–2023. The rising prevalence of hypertension and diabetes and the high public awareness related to the early diagnosis and management of these disorders are the key factors assisting the overall ACE inhibitor market. According to the World Health Organization (WHO), globally, cardiovascular disease accounts for approximately 17 million deaths a year, or nearly one-third of the total.

Of these, complications of hypertension account for 9.4 million deaths worldwide every year. The global economic burden of increased blood pressure was estimated to consume US$370 billion worldwide and 10% of healthcare expenditures. ACE inhibitors also play a vital role in treating chronic kidney diseases and other cardiovascular diseases such as heart failure and myocardial infarction. The chronic kidney disorders application segment was observed as the fastest-moving segment in the overall ACE inhibitors market throughout the 2016–2023.

Based on the type of drug, the global angiotensin-converting enzyme (ACE) inhibitors market is segmented as follows:

  • Benazepril
  • Captopril
  • Enalapril
  • Fosinopril
  • Lisinopril
  • Moexipril
  • Perindopril
  • Quinapril
  • Ramipril
  • Trandolapril
  • Combination ACE inhibitors

Angiotensin-converting enzyme (ACE) inhibitors are high-blood pressure drugs that widen or dilate the blood vessels to improve the amount of blood the heart pumps and lower blood pressure. About half of people (50%) with high blood pressure do not have their condition under control, according to recent data from the Centers for Disease Control and Prevention and the National Health and Nutrition Examination Survey (NHANES). According to the British Hypertension Society, these drugs inhibit the activity of ACE from preventing the formation of the active octapeptide, angiotensin II, from the inactive decapeptide, angiotensin I.

This process mainly occurs in the blood and tissues, including the kidney, heart, blood vessels, adrenal gland, and brain. Angiotensin II is a potent vasoconstrictor that promotes aldosterone release and facilitates sympathetic activity, along with other potentially harmful effects on the cardiovascular system. The drop in blood pressure secondary to vasodilatation following ACE inhibition is greatest when the renin-angiotensin system is stimulated. Still, ACE inhibitors also lower blood pressure when there is normal or low activity of the renin-angiotensin system. Market experts suggest that lisinopril and ramipril are more popular than comparable drugs due to their convenience in dosage, good insurance coverage, higher efficiency, and low side effects.

For this study, the global angiotensin-converting enzyme (ACE) inhibitor market is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

In 2015, North America was observed as the largest and most potential regional market for ACE inhibitors. North America comprises the regional markets of the U.S. and Canada, and the rising prevalence of hypertension and kidney disorders is one of the key factors that assist the ACE inhibitor market in this region. The developed healthcare infrastructure, high public awareness related to lifestyle diseases and treatments, and rising research and development activities related to managing lifestyle diseases are the key factors assisting the growth of the North American ACE inhibitor market. Asia Pacific is expected to be the fastest-growing regional market for ACE inhibitors throughout the forecast period.

Over the next six years, the market's growth in the Asia-Pacific region will likely be centered in China, India, and Japan. Several factors, such as the rising prevalence of hypertension and kidney disorders and high public awareness related to the diagnosis of lifestyle diseases, are assisting the growth of the Asia-Pacific market. The other factors assisting the growth of the ACE inhibitor market are the aging population and other risk factors such as obesity, physical inactivity, and alcohol consumption in this region.

Frequently Asked Questions:

The market for Angiotensin Converting Enzyme (ACE) Inhibitors Market is expected to reach USD 11,094.6 Mn By 2023.

The Angiotensin Converting Enzyme (ACE) Inhibitors Market is expected to see significant CAGR growth over the coming years, at (0.5%).

The report is forecasted from 2016 to 2023.

The base year of this report is 2015.

Abbott Laboratories, Pfizer, Inc., Novartis AG, Merck & Co., Astra Zeneca plc, Johnson & Johnson Limited, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Aug 2016
Category:  Pharmaceuticals
Report ID:   58053
Report Format:   PDF
Pages:   120
Rating:    4.3 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support